FIG. 1




FIG. 2




FIG. 3



Regimen
BID
QD
1
2
3
4
5
6
100
10
1
Concentration (ng/mL)
336
342
348
354
360
Time (h)

FIG. 4



Part 1A
Single Agent Dose Escalation (BLRM design)
Part 2
Single Agent Dose Expansion Cohorts
NSCLC,HNSCC, Esophageal, Endometrial, Cervical and Bladder Cancer (n~40 participants)
N=80 participants
Dose Level X - MTD QD
Dose Level 7 - 8 mg QD
Dose Level 6 - 6 mg BID
Dose Level 5 - 4 mg BID
Dose Level 4 - 2 mg BID
Dose Level 3 - 1 mg BID
Dose Level 2 - 0.5 mg BID
Dose Level 1 - 0.5 mg QD
Recommended dose for expansion (RP2D)
Part 2A: 2L+NSCLC, monotherapy n=20
Part 2B: 2L+urothelial carcinoma, monotherapy, n=20
Part 2C: 2L+HNSCC, monotherapy n=20
Part 1B: 2L+NSCLC, dose finding combination with Docetaxel, n=6-9
Part 2D: 2L+NSCLC, combination with Docetaxel, n=20

FIG. 5



Steady state median concentration-time profiles for 4 mg QD
100
10
1
Concentration (ng/mL)
0
2
4
6
12
24
Time after dose (hour)

FIG. 6



Steady state median concentration-time profiles for 6 mg QD
100
10
1
Concentration (ng/mL)
0
2
4
6
12
24
Time after dose (hour)

FIG. 7




Steady state median concentration-time profiles for 8 mg QD
100
10
1
Concentration (ng/mL)
0
2
4
6
12
24
Time after dose (hour)

FIG. 8


100
80
60
40
20
0
% Inhibition in plasma SDMA
0 1
7
14
21
28
Time (day)
Dose
1 0.5 mg QD
2 0.5 mg BID
3 1 mg BID
4 2 mg BID
5 4 mg BID
6 6 mg BID
7 8 mg QD
8 6 mg QD
9 4 mg QD